Business Combinations (Tables)

12 Months Ended

Sep. 28, 2019

The following unaudited pro forma information presents the combined financial results for the Company and Cynosure as if the acquisition of Cynosure had been completed at the beginning of the prior fiscal year, September 26, 2015 (the first day of fiscal 2016):



	Year Ended
	September 30, 2017
Revenue	$	3,241.4
Net income	$	768.5
Basic earnings per common share	$	2.75
Diluted earnings per common share	$	2.69

Cynosure

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

The total purchase price was allocated to Cynosure’s tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of March 22, 2017, as set forth below:



Cash	$	107.2
Marketable securities	82.9
Accounts receivable	40.2
Inventory	120.0
Property, plant and equipment	44.1
Other assets and liabilities, net	11.9
Accounts payable and accrued expenses	(76.6		)
Deferred revenue	(11.2		)
Capital lease obligation	(25.2		)
Identifiable intangible assets:
Developed technology	736.0
In-process research and development	107.0
Distribution agreement	42.0
Customer relationships	35.0
Trade names	74.0
Deferred income taxes, net	(315.2		)
Goodwill	685.7
Purchase Price	$	1,657.8

Faxitron

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

The total purchase price was allocated to Faxitron's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of July 31, 2018, as set forth below:



Cash	$	2.4
Accounts receivable	4.0
Inventory	5.8
Other assets	3.1
Accounts payable and accrued expenses	(8.8		)
Deferred revenue	(1.9		)
Long-term debt	(3.3		)
Identifiable intangible assets:
Developed technology	44.9
In-process research and development	5.5
Customer relationships	0.5
Trade names	2.3
Deferred income taxes, net	(10.6		)
Goodwill	45.6
Purchase Price	$	89.5

Focal Therapeutics

Business Acquisition [Line Items]

Schedule of Purchase Price Allocation

The total purchase price was allocated to Focal's tangible and identifiable intangible assets and liabilities based on the estimated fair values of those assets as of October 1, 2018, as set forth below:



Cash	$	2.2
Accounts receivable	2.0
Inventory	7.9
Other assets	0.5
Accounts payable and accrued expenses	(5.6		)
Long-term debt	(2.5		)
Identifiable intangible assets:
Developed technology	83.1
In-process research and development	11.4
Trade names	2.7
Deferred income taxes, net	(12.7		)
Goodwill	31.1
Purchase Price	$	120.1